Patents by Inventor Emmanuel Nony

Emmanuel Nony has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Markers of immune response
    Patent number: 11015221
    Abstract: The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 25, 2021
    Assignee: STALLERGENES
    Inventors: Laurent Mascarell, Claire Gueguen, Emmanuel Nony, Philippe Moingeon, Véronique Bodo
  • Sialylated fetuin-A as a marker of immunotherapy efficacy
    Patent number: 10884002
    Abstract: The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: January 5, 2021
    Assignee: STALLERGENES
    Inventors: Vincent Lombardi, Noémie Caillot, Emmanuel Nony, Philippe Moingeon, Véronique Bodo, Julien Bouley
  • Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units
    Patent number: 10364425
    Abstract: The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the rate of Gal?1,3G al glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: July 30, 2019
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Abdessatar Sami Chtourou, Emmanuel Nony, Nicolas Bihoreau
  • Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units
    Patent number: 10344272
    Abstract: The invention is related to a composition of recombinant or transgenic Factor VII, each molecule of Factor VII of the composition exhibiting two N-glycosylation sites, wherein, among all the molecules of FVII of the composition, the proportion of Gal?1,3Gal glycan moieties is comprised between 0 and 4%. The invention is also related to a process for preparing such a composition of FVII.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: July 9, 2019
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Abdessatar Sami Chtourou, Emmanuel Nony, Nicolas Bihoreau
  • Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
    Patent number: 10190166
    Abstract: The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector T cell response, and methods of determining response to immunotherapy.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 29, 2019
    Assignee: STALLERGENES
    Inventors: Philippe Moingeon, Aline Zimmer, Julien Bouley, Laurent Mascarell, Emmanuel Nony
  • Biomarkers of immunotherapy efficacy
    Patent number: 10101341
    Abstract: The invention relates to proteins for use as markers for the efficacy of sublingual immunotherapy. In particular, the proteins may be used to predict the responsiveness of a patient to immunotherapy. The invention may find use in selecting patients as suitable candidates for immunotherapy.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: October 16, 2018
    Assignee: STALLERGENES
    Inventors: Véronique Bodo, Philippe Moingeon, Julien Bouley, Emmanuel Nony, Hélène Moussu, Karine Jain
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 10081683
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: September 25, 2018
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe de Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Use of ADCC-optimized antibodies for treating low-responder patients
    Patent number: 9879089
    Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: January 30, 2018
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Dominique Bourel, Sylvie Jorieux, Christophe de Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony
  • Recombinant Der P 2 expressed in Pichia Pastoris as a “natural-like” allergen for immunotherapy and diagnostic purposes
    Patent number: 9868770
    Abstract: The present invention concerns a method for producing a recombinant Dermatophagoides pteronyssinus 2 protein (rDer p 2), comprising the steps of cultivating a Pichia pastoris yeast strain previously transformed with a rDer p 2 coding sequence, and isolating the rDer p 2 protein from said Pichia pastoris yeast strain. The invention also relates to compositions and kits comprising the rDer p 2 protein for therapeutic or diagnostic use.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: January 16, 2018
    Assignee: STALLERGENES
    Inventors: Véronique Bordas, Laetitia Bussieres, Sabi Airouche, Sophie Tourdot, Emmanuel Nony, Philippe Moingeon, Julien Bouley
  • MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION
    Publication number: 20180002442
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.
    Type: Application
    Filed: June 7, 2017
    Publication date: January 4, 2018
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: ROLAND BELIARD, Dominique BOUREL, Arnaud GLACET, Christophe de ROMEUF, Nicolas BIHOREAU, Emmanuel NONY
  • SIALYLATED FETUIN-A AS A MARKER OF IMMUNOTHERAPY EFFICACY
    Publication number: 20170370946
    Abstract: The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.
    Type: Application
    Filed: November 23, 2015
    Publication date: December 28, 2017
    Inventors: Vincent LOMBARDI, Noémie CAILLOT, Emmanuel NONY, Philippe MOINGEON, Véronique BODO, Julien BOULEY
  • Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa
    Patent number: 9822185
    Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: November 21, 2017
    Assignee: STALLERGENES
    Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
  • MARKERS OF IMMUNE RESPONSE
    Publication number: 20170233816
    Abstract: The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory T cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.
    Type: Application
    Filed: October 29, 2015
    Publication date: August 17, 2017
    Inventors: Laurent MASCARELL, Claire GUEGUEN, Emmanuel NONY, Philippe MOINGEON, Véronique BODO
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9718889
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: August 1, 2017
    Assignee: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Amaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9718890
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 1, 2017
    Assignee: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • Monoclonal antibodies with enhanced ADCC function
    Patent number: 9708409
    Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: July 18, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
  • COMPOSITION OF ALLERGEN EXTRACTS HAVING REDUCED TOXICITY AND METHOD OF PRODUCTION THEREOF
    Publication number: 20170157240
    Abstract: The present invention concerns pollen allergen extracts, in particular ragweed (Ambrosia) pollen allergen extracts, containing reduced amounts of copper-binding-like proteins in order to minimize the risk of toxicity, including induction of angioedema, of those allergen extracts. The invention also relates to methods of preparing pollen allergen extracts containing reduced amounts of copper-binding-like proteins.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 8, 2017
    Inventors: Emmanuel NONY, Laurent MASCARELL, Philippe MOINGEON, Thierry BATARD, Henri CHABRE, Nathalie BERJONT
  • USE OF IGG1 IMMUNOGLOBULINS AND/OR LIGANDS OF THE CD32 RECEPTOR FOR TREATING INFLAMMATORY DISEASES AND INCIDENTS VIA THE MUCOSA
    Publication number: 20160032018
    Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
    Type: Application
    Filed: October 9, 2015
    Publication date: February 4, 2016
    Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
  • Use of IgGimmunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
    Patent number: 9187568
    Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: November 17, 2015
    Assignee: STALLERGENES S.A.
    Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
  • USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS
    Publication number: 20150307624
    Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
    Type: Application
    Filed: May 1, 2015
    Publication date: October 29, 2015
    Applicant: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Dominique Bourel, Sylvie Jorieux, Christophe de Romeuf, Philippe Klein, Christine Gaucher, Nicolas Bihoreau, Emmanuel Nony